Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AG-013736 as Second- or Later-Line Treatment in Advanced Non-Small Cell Lung Cancer
2005-003501-90Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Overall response rate. Started Jun 2006; status: completed.
02
Drugs
axitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-003501-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003501-90.